The Dishevelled-3 (DVL3) antibody is a crucial tool for studying the DVL3 protein, a member of the Dishevelled (DVL) family involved in the Wnt signaling pathway. DVL proteins (DVL1. DVL2. DVL3) act as key mediators in both canonical (β-catenin-dependent) and non-canonical (β-catenin-independent) Wnt signaling, regulating processes like embryogenesis, cell polarity, proliferation, and differentiation. DVL3. specifically, plays a role in neural development, tissue homeostasis, and cancer progression. Dysregulation of DVL3 is linked to tumors (e.g., colorectal, breast cancers) and developmental disorders (e.g., neural tube defects).
DVL3 antibodies are designed to detect and quantify DVL3 expression in various experimental models. These antibodies, often monoclonal or polyclonal, enable techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). Their specificity is critical for distinguishing DVL3 from homologous family members (DVL1/DVL2), which share structural domains but may have divergent functions. Validated antibodies aid in exploring DVL3’s interactions with Wnt pathway components (e.g., Frizzled receptors, β-catenin) and its post-translational modifications. Researchers also use DVL3 antibodies to investigate its oncogenic potential, including overexpression in cancers and crosstalk with other signaling pathways (e.g., Notch, Hippo). As Wnt signaling gains attention in therapeutic targeting, DVL3 antibodies remain essential for mechanistic studies and biomarker development.